-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明,無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Jaguar Health Reports Voting Results From 2022 Special Meeting of Stockholders
Jaguar Health Reports Voting Results From 2022 Special Meeting of Stockholders
All Proposals Approved
SAN FRANCISCO, CA / ACCESSWIRE / September 30, 2022 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced the voting results of the Company's 2022 Special Meeting of Stockholders held on September 30, 2022.
Four proposals were submitted to and approved by the stockholders of the Company at the Special Meeting. The proposals are described in detail in the Company's definitive proxy statement on Schedule 14A relating to the Special Meeting filed with the Securities and Exchange Commission on August 29, 2022. Stockholders may obtain a free copy of the proxy statement filed by Jaguar with the SEC at The proxy statement is also available on the Company's corporate website.
About Jaguar Health, Napo Pharmaceuticals, Napo Therapeutics & Jaguar Animal Health
Jaguar Health, Inc. is a commercial stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, including chronic, debilitating diarrhea. Jaguar Health's wholly owned subsidiary, Napo Pharmaceuticals, Inc., focuses on developing and commercializing proprietary plant-based human pharmaceuticals from plants harvested responsibly from rainforest areas. Our crofelemer drug product candidate is the subject of the OnTarget study, an ongoing pivotal Phase 3 clinical trial for prophylaxis of diarrhea in adult cancer patients receiving targeted therapy. Jaguar Health is the majority shareholder of Napo Therapeutics S.p.A. (f/k/a Napo EU S.p.A.), an Italian corporation established by Jaguar Health in Milan, Italy in 2021 that focuses on expanding crofelemer access in Europe. Jaguar Animal Health is a tradename of Jaguar Health.
For more information about Jaguar Health, please visit For more information about Napo Pharmaceuticals, visit .
Forward-Looking Statements
Certain statements in this press release constitute "forward-looking statements." In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expect," "plan," "aim," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "estimate," "predict," "potential" or "continue" or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar's control. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.
Contact:
Peter Hodge
Jaguar Health, Inc.
phodge@jaguar.health
Jaguar-JAGX
SOURCE: Jaguar Health, Inc.
View source version on accesswire.com:
All Proposals Approved
已核准所有提案
SAN FRANCISCO, CA / ACCESSWIRE / September 30, 2022 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced the voting results of the Company's 2022 Special Meeting of Stockholders held on September 30, 2022.
加利福尼亞州三藩市/交通資訊/2022 年 9 月 30 日/ 捷豹健康股份有限公司(NASDAQ:JAGX)(簡稱「捷豹」或「公司」)今天宣布了 2022 年 9 月 30 日舉行的公司 2022 年股東特別大會的投票結果。
Four proposals were submitted to and approved by the stockholders of the Company at the Special Meeting. The proposals are described in detail in the Company's definitive proxy statement on Schedule 14A relating to the Special Meeting filed with the Securities and Exchange Commission on August 29, 2022. Stockholders may obtain a free copy of the proxy statement filed by Jaguar with the SEC at The proxy statement is also available on the Company's corporate website.
在特別會議上向公司股東提交了四份提案並獲得了股東批准。該公司就 2022 年 8 月 29 日向美國證券交易委員會提交的特別會議有關的附表 14A 的最終代表聲明中詳細描述有關建議。股東可免費索取 Jaguar 向 SEC 提交的代理聲明的免費副本,該代表聲明也可在公司網站上找到。
About Jaguar Health, Napo Pharmaceuticals, Napo Therapeutics & Jaguar Animal Health
關於捷豹健康,Napo 製藥,Napo 治療和捷豹動物健康
Jaguar Health, Inc. is a commercial stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, including chronic, debilitating diarrhea. Jaguar Health's wholly owned subsidiary, Napo Pharmaceuticals, Inc., focuses on developing and commercializing proprietary plant-based human pharmaceuticals from plants harvested responsibly from rainforest areas. Our crofelemer drug product candidate is the subject of the OnTarget study, an ongoing pivotal Phase 3 clinical trial for prophylaxis of diarrhea in adult cancer patients receiving targeted therapy. Jaguar Health is the majority shareholder of Napo Therapeutics S.p.A. (f/k/a Napo EU S.p.A.), an Italian corporation established by Jaguar Health in Milan, Italy in 2021 that focuses on expanding crofelemer access in Europe. Jaguar Animal Health is a tradename of Jaguar Health.
Jaguar Health, Inc. 是一家商業階段製藥公司,專注於為患有胃腸道疾病的人和動物開發新穎,基於植物,非阿片類藥物和可持續衍生的處方藥,包括慢性,衰弱的腹瀉。Jaguar Health 的全資子公司 Napo 製藥公司,致力於從雨林地區負責任地收穫的植物中開發和商業化以植物為基礎的專有人類藥品。我們的 Crofelemer 候選藥物候選藥物是 OnTarget 研究的主題,該研究是一項正在進行的關鍵性 3 期臨床試驗,用於預防接受標靶治療的成年癌症患者腹瀉。捷豹健康是 Napo 治療藥物公司(f/k/a Napo 歐盟股份有限公司)的主要股東,該公司是捷豹健康於 2021 年在意大利米蘭成立的意大利公司,致力於擴大歐洲的鱷魚訪問。捷豹動物健康是捷豹健康的貿易商。
For more information about Jaguar Health, please visit For more information about Napo Pharmaceuticals, visit .
有關更多信息捷豹健康,請訪問有關 Napo 製藥的更多信息,請訪問。
Forward-Looking Statements
前瞻性陳述
Certain statements in this press release constitute "forward-looking statements." In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expect," "plan," "aim," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "estimate," "predict," "potential" or "continue" or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar's control. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.
本新聞稿中的某些陳述構成「前瞻性陳述」。在某些情況下,您可以通過諸如「可能」,「意志」,「應該」,「期望」,「計劃」,「目標」,「預測」,「可能」,「意圖」,「目標」,「項目」,「思考」,「相信」,「估計」,「預測」,「預測」,「潛在」,「目標」,「項目」,「思考」,「相信」,「估計」,「預測」,「潛在」或「繼續」其他術語的負面表達。此版本中的前瞻性陳述只是預測。Jaguar 基於這些前瞻性陳述,主要基於其目前對未來事件的預期和預測。這些前瞻性陳述僅在本發布之日起發表,並且受到許多風險,不確定性和假設的影響,其中一些無法預測或量化,其中一些超出了 Jaguar 的控制範圍。除適用法律要求外,Jaguar 不打算公開更新或修改此處包含的任何前瞻性聲明,無論是由於任何新信息,未來事件,情況變化或其他原因造成的。
Contact:
聯繫方式:
Peter Hodge
Jaguar Health, Inc.
phodge@jaguar.health
Jaguar-JAGX
彼得·霍奇
捷豹健康有限公司
phodge@jaguar.health
美洲杰克斯
SOURCE: Jaguar Health, Inc.
來源: 捷豹健康有限公司
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧